Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma
- PMID: 10791852
- DOI: 10.1007/BF02523656
Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma
Abstract
Background: A definite resolution to the controversy on the optimal extension of lymph node dissection (LND) in gastric cancer has not been achieved. Surgical morbidity and survival of D1 and D2 LND are compared by multivariate analysis.
Methods: A retrospective cohort study of 219 patients with gastric cancer and curative resection performed according to Japanese rules. D1 dissection was performed in 106 cases and D2 in 113. The logistic regression model was used to define risk factors for surgical morbidity and the Cox model to determine prognostic factors.
Results: Surgical morbidity occurs in 16.9% and 19.5% in D1 and D2 LND, respectively (P = .7). The morbidity determinants were operation blood loss, splenectomy, pancreaticosplenectomy, antrum location, low serum albumin, total gastrectomy, and metastatic nodal ratio (P < .0001), but not D2 LND. Five-year survival was 35.1% for D1 and 64% for D2 LND (P < .039). The prognostic factors were T stage, N stage, serum albumin level, total gastrectomy, D2 LND, and comorbidity (P < .0001).
Conclusions: The increment of surgical morbidity and mortality rates attributed to D2 LND is largely caused by the effect of splenectomy and pancreaticosplenectomy. A significant survival benefit because of D2 LND was found. The results support the value of extended LND in the surgical treatment of gastric cancer.
Similar articles
-
Comparison of long term survival outcomes between D1+ and D2 lymph node dissection for ≥ pT2 or pN+ gastric carcinoma: A large scale case-control study using propensity score matching.Eur J Surg Oncol. 2020 Jul;46(7):1239-1246. doi: 10.1016/j.ejso.2020.04.013. Epub 2020 Apr 14. Eur J Surg Oncol. 2020. PMID: 32331983
-
The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma.J Am Coll Surg. 1995 Jul;181(1):56-64. J Am Coll Surg. 1995. PMID: 7599772
-
The Turkish experience with curative gastrectomies for gastric carcinoma: is D2 dissection worthwhile?J Am Coll Surg. 2001 Jan;192(1):25-37. doi: 10.1016/s1072-7515(00)00779-1. J Am Coll Surg. 2001. PMID: 11192920
-
Gastric cancer: Current status of lymph node dissection.World J Gastroenterol. 2016 Mar 14;22(10):2875-93. doi: 10.3748/wjg.v22.i10.2875. World J Gastroenterol. 2016. PMID: 26973384 Free PMC article. Review.
-
Lymph node dissection in resectable advanced gastric cancer.Dig Surg. 2013;30(2):96-103. doi: 10.1159/000350873. Epub 2013 Jul 18. Dig Surg. 2013. PMID: 23867585 Review.
Cited by
-
Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer: an update meta-analysis based on randomized controlled trials.Surg Endosc. 2013 Jul;27(7):2466-80. doi: 10.1007/s00464-012-2758-6. Epub 2013 Jan 30. Surg Endosc. 2013. PMID: 23361259 Review.
-
Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection.Surg Endosc. 2012 Jul;26(7):1813-21. doi: 10.1007/s00464-011-2118-y. Epub 2012 Feb 21. Surg Endosc. 2012. PMID: 22350227
-
Modified radical lymphadenectomy (D1.5) for T2-3 gastric cancer.Langenbecks Arch Surg. 2005 Sep;390(5):397-402. doi: 10.1007/s00423-005-0570-7. Epub 2005 Jul 22. Langenbecks Arch Surg. 2005. PMID: 16041552
-
Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma.Surg Endosc. 2008 Dec;22(12):2753-60. doi: 10.1007/s00464-008-0129-0. Epub 2008 Sep 24. Surg Endosc. 2008. PMID: 18813994 Clinical Trial.
-
Lymph node involvement in gastric cancer for different tumor sites and T stage: Italian Research Group for Gastric Cancer (IRGGC) experience.J Gastrointest Surg. 2007 Sep;11(9):1146-53. doi: 10.1007/s11605-006-0062-2. J Gastrointest Surg. 2007. PMID: 17576611
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
